Literature DB >> 23295401

Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's disease model.

Sherry A Ferguson1, Sumit Sarkar, Larry C Schmued.   

Abstract

The APP/PS1 double transgenic mouse is an Alzheimer's Disease-like model. However, cognitive deficits measured at one age do not necessarily indicate age-related progressions. Further, results of the most widely used behavioral assessment, water maze performance, are generally limited to 1-2 endpoints. Here, male APP/PS1 and noncarrier wildtypes (n=11/group) were assessed at 7-15 months of age for water maze, open field, and motor coordination performance. Body weights and motor coordination were comparable for both groups throughout. Beginning at approximately 9 months of age, the transgenic group exhibited hypoactivity in the open field which continued throughout. Latency to locate the platform and swim path length were longer in the transgenic group; however, these appeared to be more related to increased floating and thigmotactic behavior and only partially related to a cognitive impairment. Age-related decrements in performance were not substantial; however, substantial plaque numbers were measured in six representative 16-month-old transgenic mice. The stability of water maze performance may be related to the longitudinal testing and repetitive experience, which previous research has demonstrated can confer beneficial effects on behavior and plaque deposition in transgenic Alzheimer's Disease models [1]. These results emphasize the importance of measuring multiple water maze endpoints and demonstrate the feasibility of longitudinal assessments in this model. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295401     DOI: 10.1016/j.bbr.2012.12.055

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  19 in total

1.  Dietary composition affects the development of cognitive deficits in WT and Tg AD model mice.

Authors:  Inga Kadish; Ashish Kumar; Ulrika Beitnere; Emily Jennings; William McGilberry; Thomas van Groen
Journal:  Exp Gerontol       Date:  2016-05-07       Impact factor: 4.032

2.  Effects of Cyclophosphamide and/or Doxorubicin in a Murine Model of Postchemotherapy Cognitive Impairment.

Authors:  Timothy J Flanigan; Julie E Anderson; Ikram Elayan; Antiño R Allen; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

Review 3.  Animal Models of Psychosis in Alzheimer Disease.

Authors:  Josh M Krivinko; Jeremy Koppel; Alena Savonenko; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-05-17       Impact factor: 4.105

4.  Longitudinal Assessment of Working Memory Performance in the APPswe/PSEN1dE9 Mouse Model of Alzheimer's Disease Using an Automated Figure-8-Maze.

Authors:  Fran C van Heusden; Sara Palacín I Bonsón; Oliver Stiedl; August B Smit; Ronald E van Kesteren
Journal:  Front Behav Neurosci       Date:  2021-05-13       Impact factor: 3.558

5.  Comparison of memory, affective behavior, and neuropathology in APPNLGF knock-in mice to 5xFAD and APP/PS1 mice.

Authors:  Andrea Locci; Hector Orellana; Guadalupe Rodriguez; Meredith Gottliebson; Bryan McClarty; Sky Dominguez; Rachel Keszycki; Hongxin Dong
Journal:  Behav Brain Res       Date:  2021-02-16       Impact factor: 3.352

6.  Early loss of cerebellar Purkinje cells in human and a transgenic mouse model of Alzheimer's disease.

Authors:  Kiran Chaudhari; Linshu Wang; Jonas Kruse; Ali Winters; Nathalie Sumien; Ritu Shetty; Jude Prah; Ran Liu; Jiong Shi; Michael Forster; Shao-Hua Yang
Journal:  Neurol Res       Date:  2021-03-10       Impact factor: 2.529

7.  Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome.

Authors:  Larisa V Lysenko; Jeesun Kim; Cassandra Henry; Anna Tyrtyshnaia; Rebecca A Kohnz; Francisco Madamba; Gabriel M Simon; Natalia E Kleschevnikova; Daniel K Nomura; R Alan B Ezekowitz; Alexander M Kleschevnikov
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

8.  The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to β-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment.

Authors:  Valeriy G Ostapchenko; Megan Chen; Monica S Guzman; Yu-Feng Xie; Natalie Lavine; Jue Fan; Flavio H Beraldo; Amanda C Martyn; Jillian C Belrose; Yasuo Mori; John F MacDonald; Vania F Prado; Marco A M Prado; Michael F Jackson
Journal:  J Neurosci       Date:  2015-11-11       Impact factor: 6.167

9.  A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer's disease.

Authors:  Iván Carrera; Ignacio Etcheverría; Lucía Fernández-Novoa; Valter Ruggero Maria Lombardi; Madepalli Krishnappa Lakshmana; Ramón Cacabelos; Carmen Vigo
Journal:  Biomed Res Int       Date:  2015-02-11       Impact factor: 3.411

10.  Long-term running exercise alleviates cognitive dysfunction in APP/PSEN1 transgenic mice via enhancing brain lysosomal function.

Authors:  Xue Wang; Yu-Ting Zhu; Yi Zhu; Yan-Ling Sun; Jun Huang; Zhe Li; Yan Wang; Jun-Chao Wu; Zheng-Hong Qin; Fang Lin
Journal:  Acta Pharmacol Sin       Date:  2021-07-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.